Toronto's Specific Biologics Raises US$35-Million to Advance ALS Gene Therapy
Specific Biologics has closed a US$35-million venture round to push its Dualase gene-editing therapy toward human trials in ALS by 2028.
Nov 2, 2026 · 4 min read
193 views